Unicycive Therapeutics (UNCY)
Nasdaq Market Closed
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines for kidney-related disorders, an area where treatment options can be limited and patient needs are often complex. The company’s work is centered on therapies intended for people with chronic kidney disease and acute kidney injury, two conditions associated with significant medical burden and high levels of specialist care.
Its lead program is oxylanthanum carbonate, commonly referred to as OLC, an investigational phosphate binder designed to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Hyperphosphatemia occurs when phosphate levels in the blood become elevated, a common complication for dialysis patients that can contribute to serious cardiovascular and bone-related problems. Phosphate binders are an established category, but Unicycive is seeking to differentiate OLC through its formulation and potential dosing profile.
The company is also advancing UNI-494, a drug candidate being studied for acute kidney injury. Acute kidney injury can develop rapidly in hospital settings and is associated with poor outcomes, particularly in vulnerable patients. By targeting this indication, Unicycive is pursuing a market with substantial unmet need and limited approved pharmacological therapies.
As a biotechnology company without a broad commercial portfolio, Unicycive’s investment profile is closely tied to clinical progress, regulatory milestones, financing needs, and the eventual market potential of its pipeline. Its strategy is to identify and develop renal disease assets that may address practical treatment challenges for nephrologists, dialysis providers, and patients.
Last updated
- Market Cap
- $149,291,997
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- $111,920,997
- Sector
- Materials
- Industry
- Pharmaceutical Preparations
- Address
- 1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW, CA, 94040
Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors
Important Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR): Soleno Therapeutics, Inc. (NASDAQ: SLNO); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Investigating Claims on Your Behalf
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Quantum, Unicycive, Fly-E, and Lantheus on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
The Gross Law Firm Reminds Unicycive Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025 – UNCY
ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important October 14 Deadline in Securities Fraud Lawsuit – UNCY
UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics (UNCY) and KinderCare Learning Companies, Inc. (KLC)
UNICYCIVE REMINDER: Bragar Eagel & Squire, P.C. Urges Investor to Contact the Firm Before the October 14th Deadline
ROSEN, REGARDED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important October 14 Deadline in Securities Fraud Lawsuit – UNCY
UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY
UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive
UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY
UNICYCIVE LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Unicycive to Contact the Firm Regarding Filed Class Action Lawsuit Before October 14th
UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY
Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers – UNCY
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Fraud Lawsuit – UNCY
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $149,291,997
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $111,920,997
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 3.96
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -3.74
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -1.46
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -$28,671,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -105.95%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -62.03%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.4
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.4
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.41
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $2,339,593
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 5.45
Income Statement
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Revenue | — | — | 675K | 951K | — |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 |
| Gross profit | — | — | 675K | 951K | 0 |
| Operating income | -29.52M | -32.12M | -20.77M | -18.05M | -8.98M |
| EBITDA | -29.48M | -32.1M | -20.77M | -18.05M | -8.96M |
| Net income | -26.56M | -37.82M | -31.41M | -18.06M | -10.02M |
| Interest expense | -71K | -71K | -82K | -6K | -628K |
| Other operating expenses | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 29.52M | 32.12M | 21.45M | 19M | 8.98M |
| Basic EPS | -1.67 | -5.65 | -12.8 | -12 | -8.6 |
| Diluted EPS | -1.67 | -5.65 | -12.8 | -12 | -8.6 |
Balance Sheet
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Total assets | 49.14M | 31.67M | 14.19M | 2.82M | 18.74M |
| Total liabilities | 18.94M | 24.24M | 18M | 3.28M | 2.26M |
| Total equity | 30.2M | 7.43M | -3.81M | -466K | 16.48M |
| Cash & equivalents | 29.2M | 26.14M | 9.7M | 455K | 16.58M |
| Current assets | 48.96M | 30.95M | 13.4M | 2.64M | 18.41M |
| Current liabilities | 18.94M | 24.12M | 17.53M | 3.28M | 2.11M |
| Accounts payable | 383K | 1.06M | 839K | 892K | 742K |
| Receivables | 0 | 0 | 0 | 0 | 0 |
Cash Flow
| Line Item | 2025 Q4 | 2024 Q4 | 2023 Q4 | 2022 Q4 | 2021 Q4 |
|---|---|---|---|---|---|
| Operating cash flow | -31.32M | -28.58M | -18.28M | -15.65M | -7.96M |
| Investing cash flow | -12.1M | -72K | -12K | -2K | -29K |
| Financing cash flow | 46.47M | 45.09M | 27.54M | -471K | 24.57M |
| Change in cash | 3.06M | 16.44M | 9.25M | -16.12M | 16.58M |
| Net income | -26.56M | -36.73M | -30.54M | -18.06M | -10.02M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13G/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Unicycive Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 144 — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | DEFA14A — Unicycive Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 4/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 4/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 4/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 4/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 4/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | EFFECT — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | S-3 — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Unicycive Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Unicycive Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Laumas Sandeep | View Filing | |
| form 4 | Form 4 — Laumas Sandeep | View Filing | |
| form 4 | Form 4 — Gupta Pramod | View Filing | |
| form 4 | Form 4 — Townsend John | View Filing | |
| form 4 | Form 4 — Jermasek Douglas | View Filing | |
| form 4 | Form 4 — Kenkare-Mitra Sara | View Filing | |
| form 4 | Form 4 — Kenkare-Mitra Sara | View Filing | |
| form 4 | Form 4 — Gupta Shalabh K. | View Filing | |
| form 4 | Form 4 — Jermasek Douglas | View Filing | |
| form 4 | Form 4 — Townsend John | View Filing | |
| form 4 | Form 4 — Gupta Pramod | View Filing | |
| form 4 | Form 4 — Laumas Sandeep | View Filing | |
| form 4 | Form 4 — Laumas Sandeep | View Filing | |
| form 4 | Form 4 — Kenkare-Mitra Sara | View Filing | |
| form 4 | Form 4 — Kenkare-Mitra Sara | View Filing | |
| form 4 | Form 4 — Gupta Shalabh K. | View Filing | |
| edgar index | 10-Q — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Unicycive Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | S-8 — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | DEF 14A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | DEFA14A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | ARS — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Unicycive Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-K — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Unicycive Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 424B5 — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Unicycive Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — Unicycive Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Unicycive Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Unicycive Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Unicycive Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Aggarwal Gaurav | View Filing | |
| form 4 | Form 4 — Aggarwal Gaurav | View Filing | |
| edgar index | 8-K — Unicycive Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Unicycive Therapeutics, Inc. | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free